BioCardia takes a new and comprehensive approach to heart failure
We are a clinical-stage regenerative medicine company developing novel therapies to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs.
Discover us
Financials & Filings
Review our corporate financial reports and SEC filings
Press Releases
Read about our latest company milestones
Clinical Trials
Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study
Product Pipeline
Learn about our product development programs and obtain an at-a-glance view of their current status
News
04 Mar

Henry Ford Health System
Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
08 Feb

15 Sep

03 Aug

Pharmaceutical Technology
BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
28 Jul

10 Jan

28 Oct

Cardiology Today
Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
11 May

University of Minnesota
Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
31 Jan

press releases
Have questions?
CALL US NOW
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
EMAIL US NOW
: info@biocardia.com
biocardia takes a new and comprehensive
approach to heart failure
By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.